Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
Agenus Reports First Quarter 2024 Results
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer